About NeuracleGenetics
NeuracleGenetics is a company based in Seoul (South Korea) founded in 2018. It operates as a B2B. NeuracleGenetics has raised $18.8 million across 1 funding round from investors including Premier Partners and Yuanta Investment. NeuracleGenetics operates in a competitive market with competitors including Freeline, StrideBio, Kate Therapeutics, Purespring Therapeutics and Coave Therapeutics, among others.
- Headquarter Seoul, South Korea
- SectorsHealthcare
- Website neuraclegen.com
- Total Equity Funding$18.8M (USD)
in 1 rounds
- Latest Funding Round$18.8M (USD), Series C
Sep 2025
- InvestorsPremier Partners
& 1 more
Funding Insights of NeuracleGenetics
NeuracleGenetics has successfully raised a total of $18.8M through 1 strategic funding round. The most recent funding activity was a Series C round of $18.8 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.8M
- Total Rounds 1
- Last Round Series C — $18.8M
- First Round $18.8M
(Sep 2025)
- Investors Count 2
All 1 funding rounds of NeuracleGenetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2025 | $18.8M | Series C | – | – |
2 investors in total: 2 institutional.
Investors in NeuracleGenetics
NeuracleGenetics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Premier Partners and Yuanta Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity & venture capital firm | – | premierpartners.co.kr | - | |
- | – | yuantainvest.com | - |
Investor details for NeuracleGenetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of NeuracleGenetics
2 dated milestones of NeuracleGenetics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded NeuracleGenetics is founded.
- Funding First funding round of $18.8M.
Competitors of NeuracleGenetics
NeuracleGenetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Freeline, StrideBio, Kate Therapeutics, Purespring Therapeutics and Coave Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| freeline.life | 2015 | Stevenage, United Kingdom | $273.69M | 152 | Gene therapy platform is developed for chronic disease treatments. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| katetherapeutics.com | 2020 | San Diego, United States | $123.78M | 46 | AAV-based gene therapies for muscle diseases are developed. | |
| purespringtx.com | 2020 | London, United Kingdom | $164M | – | Developer of therapeutics for chronic renal diseases | |
| coavetx.com | 2014 | Paris, France | $77.03M | – | Gene therapies for ocular and neurological diseases are developed. | |
| opusgtx.com | 2021 | Durham, United States | $23.5M | – | Gene therapies for retinal degenerative diseases are developed. | |
| regenxbio.com | 2008 | Rockville, United States | $108.39M | 344 | AAV gene therapy is developed for rare genetic diseases. | |
| aavantgardebio.com | 2021 | Milan, Italy | $65.27M | – | Developer of gene therapies for inherited retinal disorders | |
| saniarx.com | 2020 | New York, United States | $11.55M | 5 | Developer of gene therapies to treat neurological diseases | |
| sirenbiotechnology.com | 2021 | San Francisco, United States | $19.61M | – | Developer of gene therapies for cancer treatments |
Detailed competitors of NeuracleGenetics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to NeuracleGenetics
10 companies that operate in the same segment as NeuracleGenetics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NeuracleGenetics
NeuracleGenetics was founded in 2018 and raised its 1st funding round 7 years after it was founded.
NeuracleGenetics is headquartered in Seoul, South Korea.
NeuracleGenetics is a funded company, having raised a total of $18.8M across 1 funding round to date. The company's 1st funding round was a Series C of $18.8M, raised on Sep 2025.
NeuracleGenetics, based in Seoul, focuses on healthcare and biotechnology, advancing biotech innovations, gene therapy, and viral vector technologies. Develops gene therapies using adeno-associated virus technology to treat various diseases. The company prioritizes operational excellence, innovation, and customer-centric approaches for success.
NeuracleGenetics's top competitors include Freeline, Regenxbio and Kate Therapeutics.
NeuracleGenetics has 2 investors. Key investors include Premier Partners, and Yuanta Investment.